Pathstone Holdings’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.41M | Buy |
11,255
+2,802
| +33% | +$352K | 0.01% | 1200 |
|
|
2025
Q1 | $935K | Sell |
8,453
-374
| -4% | -$41.4K | ﹤0.01% | 1416 |
|
|
2024
Q4 | $1.2M | Buy |
8,827
+1,980
| +29% | +$270K | 0.01% | 1263 |
|
|
2024
Q3 | $789K | Sell |
6,847
-2,696
| -28% | -$311K | ﹤0.01% | 1491 |
|
|
2024
Q2 | $1.31M | Buy |
9,543
+4,206
| +79% | +$579K | 0.01% | 1162 |
|
|
2024
Q1 | $736K | Sell |
5,337
-1,031
| -16% | -$142K | ﹤0.01% | 1476 |
|
|
2023
Q4 | $839K | Buy |
+6,368
| New | +$839K | ﹤0.01% | 1169 |
|